VOYAGER THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: To elect each of the following directors to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Jude Onyia

VOYAGER THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jude Onyia, Ph.D.”): 34,864,862 for, 2,933,199 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(a) Voyager's stockholders elected Michael Higgins, Jude Onyia, Ph.D., and Nancy Vitale, each to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, subject to his or her earlier death, resignation, or remov…”
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 9,522,540 for, 1,913,126 withheld, 15,077 abstained.

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.

Description as filed by funds: To elect each of the following directors to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Michael Higgins

VOYAGER THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael Higgins”): 30,865,370 for, 6,932,691 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(a) Voyager's stockholders elected Michael Higgins, Jude Onyia, Ph.D., and Nancy Vitale, each to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, subject to his or her earlier death, resignation, or remov…”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 8,707,034 for, 2,642,986 withheld, 100,723 abstained.

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.

Description as filed by funds: To elect each of the following directors to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Nancy Vitale

VOYAGER THERAPEUTICS INC.’s own tally for this item (“Elect Director: Nancy Vitale”): 31,262,994 for, 6,535,067 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(a) Voyager's stockholders elected Michael Higgins, Jude Onyia, Ph.D., and Nancy Vitale, each to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, subject to his or her earlier death, resignation, or remov…”
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 8,749,042 for, 2,600,978 withheld, 100,723 abstained.

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.

Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

VOYAGER THERAPEUTICS INC.’s own tally for this item (“Voyager's stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager's named executive officers.”): 35,949,375 for, 1,711,367 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(b) Voyager's stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager's named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 61 managers: 10,504,981 for, 945,762 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 128 managers: 18,794,403 for, 1,280,206 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

VOYAGER THERAPEUTICS INC.’s own tally for this item (“Voyager's stockholders ratified the appointment of Ernst & Young LLP as Voyager's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 46,278,029 for, 72,375 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(c) Voyager's stockholders ratified the appointment of Ernst & Young LLP as Voyager's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 11,409,386 for, 41,357 against.

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.